MedTrace Logo

Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in PNH Patients.

NCT07212426 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-01-16

No results posted yet for this study

Summary

This is a multicenter, randomized, open-label, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-005 injection in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Conditions

  • PNH - Paroxysmal Nocturnal Hemoglobinuria

Interventions

BIOLOGICAL

LP-005 Injection

IV infusion, Q4W

Sponsors & Collaborators

  • Longbio Pharma

    lead INDUSTRY

Principal Investigators

  • Guangsheng He · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-14
Primary Completion
2026-05-06
Completion
2028-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07212426 on ClinicalTrials.gov